Montgomery, Ala. — The Alabama Board of Medical Examiners is warning physicians and other licensed medical professionals across the state not to prescribe, administer, dispense or recommend non-FDA approved “research-grade” peptides, citing growing safety concerns tied to online wellness trends and social media promotion.
According to the Board, an official alert was issued reminding medical professionals that research-grade peptides are not approved by the U.S. Food and Drug Administration for human use and are not regulated for safety, effectiveness, manufacturing quality or consistency.
“Patients are increasingly exposed to online marketing that can blur the line between legitimate medicine and unregulated products. Many patients may not realize research-grade peptides are not approved for human use,” said Dr. Max Rogers, Chair of the Board of Medical Examiners.
“When a substance has not gone through FDA review, there is no reliable way to verify what it actually is, how it was manufactured or what risks it may pose. Our responsibility is to protect patients and ensure medical professionals uphold the high standards required under Alabama law.”
According to the Board, peptides have become increasingly popular online, with influencers and social media personalities promoting claims tied to muscle growth, anti-aging, weight loss, skin health and athletic performance.
The Board also referenced national media reports, including coverage by The Wall Street Journal, highlighting a rise in peptide use among teenagers and young adults seeking physical enhancement.
Officials stressed that Alabama physicians are required by law to obtain prescription drugs and ingredients only from properly permitted sources and that any medications dispensed or administered to patients must meet prescription-quality standards.
Under Alabama law, physicians, Physician Assistants (PAs), Certified Registered Nurse Practitioners (CRNPs) and Certified Nurse Midwives (CNMs) are prohibited from prescribing, administering, dispensing, recommending or supplying non-FDA approved research-grade peptides to patients.
The Board further warned that patient waivers or consent forms labeling substances as “research-grade” do not remove a provider’s legal or professional responsibilities.
The Alabama Board of Medical Examiners said it remains committed to protecting the health and safety of Alabama patients and expects all medical professionals to fully comply with state law and professional standards of care.
